Patients with heart failure with preserved ejection fraction (HFpEF) who have low plasma renin levels experience greater blood pressure reductions and improved cardiac function when treated with a combination of spironolactone and dapagliflozin, according to findings from the SOGALDI-PEF trial published in JACC: Heart Failure. The study, led by João Pedro Ferreira, MD, PhD, suggests that baseline renin levels act as a predictive marker for treatment response, while aldosterone levels do not.
Why do low renin levels predict better treatment outcomes?
In the SOGALDI-PEF trial, researchers observed that patients with baseline renin levels at or below 29.7 mU/L, specifically those at or below 21 mU/L, derived significant clinical benefits from combined therapy. According to the study, this subgroup saw systolic blood pressure drop by 10.9 mm Hg compared to those treated with dapagliflozin alone. This patient group also showed more favorable changes in lateral E/e’, pulse wave velocity, and left atrial diameter. Experts suggest these findings point toward an underlying mechanism of autonomous aldosterone production, where the mineralocorticoid pathway remains active despite low circulating renin, making these patients particularly responsive to spironolactone.
What is the relationship between renin and aldosterone in HFpEF?
The SOGALDI-PEF trial data indicates a lack of correlation between plasma renin and aldosterone levels in HFpEF patients, with a reported rho of 0.15. While traditional medical models often assume these two hormones move in tandem, the findings published in JACC: Heart Failure suggest this interdependence is not a consistent feature in this specific patient population. According to the study authors, blood pressure and echocardiographic parameters did not vary significantly based on aldosterone strata, indicating that aldosterone concentration alone is a poor predictor of how a patient will respond to this drug combination.
How does this study shift current clinical practice?
The findings offer a path toward more personalized heart failure management. Editorialists Clara Saldarriaga, MD, and Bertram Pitt, MD, noted that the results align with an evolving understanding of primary aldosteronism. They argue that low-renin hypertension likely reflects an enhanced mineralocorticoid pathway activation that remains present regardless of circulating aldosterone levels. By utilizing renin as a biomarker, physicians may move away from “one-size-fits-all” treatment and toward targeted interventions for patients with specific hemodynamic profiles.
Frequently Asked Questions
Does aldosterone concentration predict how a patient will respond to spironolactone?
No. According to the SOGALDI-PEF analysis, aldosterone levels exhibited no predictive value in determining a patient’s response to the combination of spironolactone and dapagliflozin.
What defines the “low renin” subgroup in this study?
The study categorized patients with renin levels of ≤21 mU/L as the “low renin” group, which demonstrated the most significant blood pressure and cardiac improvements during the 12-week trial period.
Are there risks associated with the spironolactone and dapagliflozin combination?
The study focused on the efficacy of the combination on cardiovascular structure and function. Patients should always consult their cardiologist regarding potential side effects, such as hyperkalemia or changes in renal function, which are common considerations when using these classes of medication.
Are you a healthcare provider interested in precision cardiology? Subscribe to our newsletter to receive the latest updates on heart failure research and clinical trial outcomes.